Literature DB >> 21383697

MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways.

C Oneyama1, J Ikeda, D Okuzaki, K Suzuki, T Kanou, Y Shintani, E Morii, M Okumura, K Aozasa, M Okada.   

Abstract

The tyrosine kinase c-Src is upregulated in various human cancers, but the molecular mechanisms underlying c-Src-mediated tumor growth remain unclear. Here we examined the involvement of microRNAs in the c-Src-mediated tumor growth. Microarray profiling revealed that c-Src activation downregulates a limited set of microRNAs, including miR-99a, which targets oncogenic mammalian target of rapamycin (mTOR) and fibroblast growth factor receptor 3 (FGFR3). Re-expression of miR-99a suppressed tumor growth of c-Src-transformed cells, and this effect was restored by the overexpression of mTOR. The downregulation of miR-99a was also observed in epidermal growth factor- and Ras-transformed cells, and it was suppressed by inhibiting the mitogen-activated protein kinase (MAPK) pathway. Furthermore, miR-99a downregulation is associated with mTOR/FGFR3 upregulation in various human lung cancer cells/tissues. The tumorigenicity of these cells was suppressed by the introduction of miR-99a. These findings suggest that the miR-99a-mTOR/FGFR3 pathway is crucial for controlling tumor growth in a wide range of human cancers that harbor upregulation of the Src-related oncogenic pathways.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21383697     DOI: 10.1038/onc.2011.63

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  57 in total

Review 1.  Tailoring mTOR-based therapy: molecular evidence and clinical challenges.

Authors:  Gaetano Santulli; Hana Totary-Jain
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

2.  Regulation of onco and tumor suppressor MiRNAs by mTORC1 inhibitor PRP-1 in human chondrosarcoma.

Authors:  Karina A Galoian; Toumy Guettouche; Biju Issac; Amir Qureshi; H T Temple
Journal:  Tumour Biol       Date:  2013-11-01

Review 3.  MicroRNA regulation of innate immune responses in epithelial cells.

Authors:  Rui Zhou; Steven P O'Hara; Xian-Ming Chen
Journal:  Cell Mol Immunol       Date:  2011-07-04       Impact factor: 11.530

Review 4.  Molecular substratification of bladder cancer: moving towards individualized patient management.

Authors:  Anirban P Mitra
Journal:  Ther Adv Urol       Date:  2016-03-28

5.  The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.

Authors:  Brittany C Parker; Matti J Annala; David E Cogdell; Kirsi J Granberg; Yan Sun; Ping Ji; Xia Li; Joy Gumin; Hong Zheng; Limei Hu; Olli Yli-Harja; Hannu Haapasalo; Tapio Visakorpi; Xiuping Liu; Chang-Gong Liu; Raymond Sawaya; Gregory N Fuller; Kexin Chen; Frederick F Lang; Matti Nykter; Wei Zhang
Journal:  J Clin Invest       Date:  2013-01-09       Impact factor: 14.808

6.  Changes in microRNA expression in the MG-63 osteosarcoma cell line compared with osteoblasts.

Authors:  Hao Hu; Yi Zhang; Xian-Hua Cai; Ji-Feng Huang; Lin Cai
Journal:  Oncol Lett       Date:  2012-08-16       Impact factor: 2.967

7.  SRC points the way to biomarkers and chemotherapeutic targets.

Authors:  Harini Krishnan; W Todd Miller; Gary S Goldberg
Journal:  Genes Cancer       Date:  2012-05

8.  IL-13 receptor α2 stimulates human glioma cell growth and metastasis through the Src/PI3K/Akt/mTOR signaling pathway.

Authors:  Ming Tu; Wei Wange; Lin Cai; Penglei Zhu; Zhichao Gao; Weiming Zheng
Journal:  Tumour Biol       Date:  2016-09-14

9.  Rapamycin-induced modulation of miRNA expression is associated with amelioration of HIV-associated nephropathy (HIVAN).

Authors:  Kang Cheng; Partab Rai; Andrei Plagov; Xiqian Lan; Peter W Mathieson; Moin A Saleem; Mohammad Husain; Ashwani Malhotra; Pravin C Singhal
Journal:  Exp Cell Res       Date:  2013-04-21       Impact factor: 3.905

10.  Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization.

Authors:  Yogin Patel; Ji S Lee; Hexin Chen
Journal:  J Vis Exp       Date:  2016-06-07       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.